Critical appraisal — melanocortin MC4R agonist
PT-141 was approved for one use, studied for several more, and the trial effect is real but modest — here is the evidence, weighed.
An independent appraisal of the bremelanotide record: the two pivotal trials, the placebo problem, the label warnings, and the line between the approved drug and the research-chemical form.
The short version
PT-141 (bremelanotide) is a lab-made peptide — a short chain of amino acids — that acts on the brain rather than on blood flow. One regulator-approved use exists: a 1.75 mg injection for premenopausal women with hypoactive sexual desire disorder, or HSDD (persistently low sexual desire that causes real distress) [3][7]. That approval rests on two large trials. The honest reading: the drug beat placebo on desire and distress, but the gap was small, and in this whole field placebo does a lot of the work [3][9]. Everything else you read about PT-141 — for men, for older women, for "performance" — is off-label or research-stage, not approved [7]. The label also warns it can briefly raise blood pressure, and nausea is common [4][7]. This site is a PT-141 reviews desk: we read the studies, weigh how good they are, and what people report — including the downsides — is on the effects page. No doses for any person, no product, no clinic.
What is PT-141
PT-141 is the development code for bremelanotide, a synthetic cyclic heptapeptide — a ring of seven amino acids — built as an analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), one of the body's own melanocortin signals [1]. It activates melanocortin receptors, chiefly MC4R and MC3R, that sit in the brain rather than in the genitals [1]. That single fact organizes the entire appraisal: PT-141 acts on the central wiring of sexual motivation, not on the plumbing of blood flow. Animal work first showed the pattern — systemic dosing produced erectile activity in rats and nonhuman primates and lit up hypothalamic neurons, and in early human work produced rapid, dose-dependent erectile responses in men with erectile dysfunction [1]. The compound carries a US-approved identity as bremelanotide and a separate, unregulated identity as a "PT-141" research chemical; this site keeps those two apart on every page [7].
What the approval actually covers — and what it does not
Bremelanotide was approved on June 21, 2019 for one indication: acquired, generalized HSDD in premenopausal women, dosed at 1.75 mg subcutaneously as needed [7]. It is not approved for men, not for postmenopausal women, and not to enhance sexual performance — despite the early erectile-dysfunction data in men [1][7]. We name that boundary first because most informal writing about PT-141 erases it. The off-label and research-chemical uses are not forbidden topics here; they are simply labeled as what they are — investigational or unapproved — wherever they appear. A fair appraisal reports the approved evidence, the off-label evidence, and the gap between them as three separate things, not one continuous claim.
How strong is the evidence, really
Two identical Phase 3 trials (the RECONNECT program, n=1267 premenopausal women with HSDD) met their coprimary endpoints: bremelanotide 1.75 mg improved a desire score by an integrated +0.35 on the Female Sexual Function Index desire domain (P<.001) and lowered desire-related distress by an integrated −0.33 on a distress item (P<.001) over 24 weeks [3]. Statistically real — and small. The appraisal community has pressed exactly this point: a meta-analysis of female sexual-dysfunction trials estimated that roughly 67.7% of the measured treatment effect was attributable to placebo, leaving the pharmacologic agents only minimally superior [9]. A 52-week open-label extension (684 women) found the benefit sustained and no new safety signals, but also documented how common nausea is at ~40% [4]. The throughline of this site: report the number, then report how much of it the placebo arm also earned.
Where this site stops
This is an editorial appraisal desk, not a pharmacy and not a clinic. We summarize and weigh published research on PT-141; we do not recommend a dose for any individual, we do not sell or source anything, and we draw a hard line between the FDA-approved bremelanotide record and the unregulated research-chemical form, which has no oversight of identity, purity, or concentration [7]. Read the PT-141 benefits the trials actually support, the full PT-141 research record, the reported PT-141 effects, and the PT-141 references behind every figure on this site.